Group 1 - Morgan Stanley Fund Management (China) has experienced performance divergence among its fund managers this year, with Lei Zhiyong's Digital Economy fund showing strong results, while Wang Dapeng's Health Industry fund underperformed the index and benchmark returns [1][2] - The Digital Economy Mixed A fund managed by Lei Zhiyong has achieved a year-to-date return of 71% as of November 9, significantly outperforming the benchmark by 46 percentage points, and ranking among the top in its category [1] - Over the past year, the Digital Economy fund has delivered nearly 80% returns, exceeding the benchmark by approximately 59 percentage points, and has achieved a remarkable 192% return over the past two years [1] Group 2 - The Health Industry Mixed A fund, managed by Wang Dapeng, has heavily invested in the popular innovative drug sector but has only realized a year-to-date return of 5%, underperforming the benchmark by nearly 11 percentage points [2] - The Health Industry fund has shown negative returns over various time frames, with returns of -2%, -16%, -27%, and -32% over the past year, two years, three years, and five years respectively, all trailing the benchmark returns [2]

Group 1 - Morgan Stanley Fund Management (China) has experienced performance divergence among its fund managers this year, with Lei Zhiyong's Digital Economy fund performing exceptionally well, while Wang Dapeng's Health Industry fund underperformed the index and benchmark returns [1][2] - The Digital Economy Mixed A fund managed by Lei Zhiyong has shown strong performance, achieving a year-to-date return of 71% as of November 9, significantly surpassing the benchmark return by 46 percentage points [1] - Over the past year, the Digital Economy fund has nearly 80% returns, exceeding the benchmark by approximately 59 percentage points, and has achieved a remarkable 192% return over the past two years [1] Group 2 - The Health Industry Mixed A fund, managed by Wang Dapeng, has heavily invested in the popular innovative drug sector but has only achieved a year-to-date return of 5%, underperforming the benchmark by nearly 11 percentage points [2] - Over longer periods, the Health Industry fund has recorded returns of -2%, -16%, -27%, and -32% over the past year, two years, three years, and five years respectively, consistently underperforming the benchmark returns [2]

Group 1 - The article provides an overview of the performance of various funds, highlighting the top and bottom performers based on net asset value updates as of July 21, 2025 [3][4]. - The top 10 funds with the highest net value growth include several ETFs focused on construction materials, indicating a strong performance in this sector [3]. - The bottom 10 funds, such as the Morgan Stanley Hong Kong-Shanghai Select Mixed Fund C, show a decline in net value, suggesting challenges in their respective strategies [4]. Group 2 - The Shanghai Composite Index experienced a rebound, with a trading volume of 1.72 trillion, and a significant number of stocks advancing compared to those declining [6]. - The construction materials and engineering machinery sectors led the market with gains exceeding 4%, reflecting positive sentiment in these industries [6]. - The fund with the fastest net value growth is the Fortune China Securities All Index Construction Materials ETF, which aligns with the strong performance of the construction materials sector [6]. Group 3 - The top holdings of the leading construction materials fund include companies like Conch Cement and North New Materials, which have shown significant price increases [7]. - The fund's style is categorized as passive index tracking, specifically following the China Securities All Index Construction Materials Index, indicating a focus on the construction materials industry [7]. - In contrast, the pharmaceutical sector funds, such as the Morgan Stanley Hong Kong-Shanghai Select Mixed Fund, have underperformed, with significant declines in key holdings like BeiGene and Zai Lab [7].

Group 1 - The core viewpoint of the news is that as of March 27, 2025, institutional investors hold a significant portion of Tiger Medical's A-shares, totaling 1.76 billion shares, which accounts for 20.31% of the company's total equity [1] - The top ten institutional investors collectively hold 14.86% of Tiger Medical's shares, with a decrease of 1.43 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two funds increased their holdings, while five funds decreased their holdings, with a total reduction rate of 0.19% [2] - A total of 16 new public funds were disclosed this period, including notable funds such as E Fund CSI 300 Medical ETF and others [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.30% compared to the previous quarter [2]